Alnylam Pharmaceuticals
NEWS
After a slight delay, things remain on schedule for Alnylam’s new $200 million manufacturing facility. The company expects the site to open in late 2019, which could follow regulatory approval of patisiran, its RNAi treatment for Hereditary ATTR Amyloidosis.
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or biotech industries.
Now that July is over, the U.S. Food and Drug Administration (FDA) appears to be back in full swing with a full docket of drug decisions to make. There are four therapeutics with PDUFA dates this week involving six biopharma companies. Here’s a look.
European Committee recommends Alnylam’s drug be approved for adults with stage 1 or stage 2 polyneuropathy.
Actor, director and advocate Rob Reiner opened the third day of the 2018 BIO International Convention.
Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
Alnylam Pharmceuticals reported preclinical results that supports advancement of its RNA interference (RNAi) therapeutics for central nervous system disorders into the clinic.
JOBS
IN THE PRESS